ARTICLE | Company News
FDA accepts Miravant's SnET2 NDA
June 1, 2004 7:00 AM UTC
The FDA accepted for filing MRVT's NDA for its PhotoPoint SnET2 tin ethyl etiopurpurin to treat wet age-related macular degeneration (AMD). The NDA has priority review designation. In 2002, data from ...